Efficacy and safety of low-dose rituximab in treatment of pediatric nephrotic syndrome: a prospective randomized controlled trial.
10.7499/j.issn.1008-8830.2301026
- Author:
Ying ZHU
1
;
Ling WU
1
;
Yun WANG
1
;
Ya-Feng ZHU
1
;
Yin PENG
1
;
Shao-Han FANG
1
;
Luo-Dan ZHANG
1
;
Fang DENG
1
Author Information
1. Department of Nephrology, Anhui Provincial Children's Hospital, Hefei 230051, China.
- Publication Type:Journal Article
- Keywords:
Child;
Frequent relapse;
Nephrotic syndrome;
Rituximab;
Steroid dependence
- MeSH:
Humans;
Child;
Nephrotic Syndrome/drug therapy*;
Rituximab/adverse effects*;
Glucocorticoids/adverse effects*;
Prospective Studies;
Adaptor Proteins, Signal Transducing
- From:
Chinese Journal of Contemporary Pediatrics
2023;25(6):606-611
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To study the efficacy and safety of repeated application of rituximab (RTX) at a low dose (200 mg/m2) versus the recommended dose (375 mg/m2) for remission maintenance in frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS).
METHODS:A randomized controlled trial was conducted for 29 children with FRNS/SDNS who received systemic treatment in the Department of Nephrology, Anhui Provincial Children's Hospital, from September 2020 to December 2021. These children were divided into a recommended dose group (n=14) and a low dose group (n=15) using a random number table. The two groups were compared in terms of general characteristics, changes in CD19 expression after RTX treatment, number of relapses, glucocorticoid dose, adverse reactions of RTX, and hospital costs.
RESULTS:After RTX treatment, both the low dose group and the recommended dose group achieved B-lymphocyte depletion and had significant reductions in the number of relapses and glucocorticoid dose (P<0.05). The low dose group had a comparable clinical effect to the recommended dose group after RTX treatment (P>0.05), and the low dose group had a significant reduction in hospital costs for the second, third, and fourth times of hospitalization (P<0.05). There were no serious adverse reactions in either group during RTX treatment and late follow-up, and there was no significant difference in adverse reactions between the two groups (P>0.05).
CONCLUSIONS:Repeated RTX treatment at a low dose has comparable clinical efficacy and safety to that at the recommended dose and can significantly reduce the number of FRNS/SDNS relapses and the amount of glucocorticoids used, with little adverse effect throughout the treatment cycle. Therefore, it holds promise for clinical application.
